Dr. Bukavina on frailty and urologic oncology

“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

The Bladder EpiCheck test received FDA 510(k) clearance in May 2023 for use in patients with NMIBC.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

At 36 months’ follow-up the gene therapy nadofaragene firadenovec demonstrated durable complete responses in patients with high-risk, BCG-unresponsive non-muscle–invasive bladder cancer.

Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.